Analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to post earnings per share of ($0.36) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Kindred Biosciences’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.37). Kindred Biosciences posted earnings of ($0.39) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.7%. The firm is scheduled to announce its next earnings report after the market closes on Thursday, August 1st.
According to Zacks, analysts expect that Kindred Biosciences will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.60) to ($1.24). For the next financial year, analysts expect that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.30) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.01). The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $1.95 million.
A number of brokerages have recently weighed in on KIN. Aegis began coverage on Kindred Biosciences in a report on Wednesday, April 10th. They issued a “buy” rating and a $16.00 price target for the company. Barclays restated a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Stifel Nicolaus set a $154.00 price objective on argenx and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Cantor Fitzgerald set a $135.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, BidaskClub upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $14.28.
Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in Kindred Biosciences during the 1st quarter worth $53,000. BNP Paribas Arbitrage SA boosted its position in Kindred Biosciences by 83,433.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,518 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 7,509 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Kindred Biosciences by 362.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 7,563 shares during the period. Meeder Asset Management Inc. boosted its position in Kindred Biosciences by 16.7% during the 1st quarter. Meeder Asset Management Inc. now owns 11,922 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,706 shares during the period. Finally, Teton Advisors Inc. boosted its position in Kindred Biosciences by 30.8% during the 1st quarter. Teton Advisors Inc. now owns 17,000 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 65.14% of the company’s stock.
Shares of NASDAQ KIN traded down $0.16 during trading on Friday, reaching $6.17. The stock had a trading volume of 1,606 shares, compared to its average volume of 176,594. Kindred Biosciences has a one year low of $6.31 and a one year high of $15.75. The company has a current ratio of 9.10, a quick ratio of 8.70 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $264.45 million, a PE ratio of -3.88 and a beta of 0.45. The stock has a 50 day simple moving average of $7.91.
About Kindred Biosciences
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Read More: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.